share print

Cell therapy pipeline

We are actively involved in the emergence of regenerative medicine by supporting enhancement of cell-based technologies through our subsidiary Celogos, experts in the restoration of tissue function and muscle regeneration.

We are currently developing two product candidates: CEL – 01, for the treatment of Urinary Incontinence (UI)  and CEL – 02, for the treatment of Fecal Incontinence (FI).


CEL-01 is a first generation, cell-based product intended for stress Urinary Incontinence (UI) treatment. CEL-01 has been evaluated in two phase II clinical trials with promising results.



CEL-02 is indicated for the treatment of Fecal Incontinence (FI); and is currently being evaluated in a phase II clinical trial.


The therapeutic cell therapy process
Celogos is a subsidiary of HRA Pharma, which focuses on cell-based technologies. The process involves isolating muscle cells or myoblasts from biopsies of a patient's muscle. These cells are then cultured, frozen, and re-injected into the patient. The myoblasts then develop into mature muscle cells, with the potential to repair the damaged tissue.

closeyou are leaving hra pharma
You are now leaving and being redirected to an external website which might not be under control of HRA Pharma.
do you want to proceed ?